Akihiro Ohmoto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4139627/publications.pdf

Version: 2024-02-01

759233 713466 46 540 12 21 citations h-index g-index papers 50 50 50 1093 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Current status of poly(ADP-ribose) polymerase inhibitors and future directions. OncoTargets and Therapy, 2017, Volume 10, 5195-5208.	2.0	96
2	Germline mutations in Japanese familial pancreatic cancer patients. Oncotarget, 2016, 7, 74227-74235.	1.8	62
3	Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future. International Journal of Molecular Sciences, 2017, 18, 143.	4.1	49
4	Genomic Features and Clinical Management of Patients with Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer. International Journal of Molecular Sciences, 2019, 20, 561.	4.1	32
5	Second morning urine method is superior to the casual urine method for estimating daily salt intake in patients with hypertension. Hypertension Research, 2012, 35, 611-616.	2.7	28
6	Clinicopathologic Features and Germline Sequence Variants in Young Patients (â‰ 4 0 Years Old) With Pancreatic Ductal Adenocarcinoma. Pancreas, 2016, 45, 1056-1061.	1.1	20
7	Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker for Anaplastic Thyroid Cancer Treated With Lenvatinib. In Vivo, 2020, 34, 2859-2864.	1.3	17
8	<p>Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary Sites and Histological Subtypes Excluded from the CheckMate-141 Trial</p> . Cancer Management and Research, 2020, Volume 12, 4161-4168.	1.9	17
9	Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma. Modern Pathology, 2021, 34, 1979-1989.	5. 5	17
10	Whole-exome Sequencing Reveals New Potential Susceptibility Genes for Japanese Familial Pancreatic Cancer. Annals of Surgery, 2020, Publish Ahead of Print, .	4.2	15
11	Anti-prion activity of protein-bound polysaccharide K in prion-infected cells and animals. Biochemical and Biophysical Research Communications, 2011, 405, 285-290.	2.1	14
12	Histopathological analysis of B-cell non-Hodgkin lymphomas without light chain restriction by using flow cytometry. Leukemia and Lymphoma, 2015, 56, 3301-3305.	1.3	14
13	Efficacy of Paclitaxel-based Chemotherapy After Progression on Nivolumab for Head and Neck Cancer. In Vivo, 2021, 35, 1211-1215.	1.3	14
14	Cyclosporine for angioimmunoblastic T-cell lymphoma: a literature review. Expert Review of Hematology, 2019, 12, 975-981.	2.2	13
15	Cardiac complications associated with hematopoietic stem-cell transplantation. Bone Marrow Transplantation, 2021, 56, 2637-2643.	2.4	11
16	Association between pretransplant iron overload determined by bone marrow pathological analysis and bacterial infection. Bone Marrow Transplantation, 2017, 52, 1201-1203.	2.4	9
17	Infection profiles of different chemotherapy regimens and the clinical feasibility of antimicrobial prophylaxis in patients with DLBCL. Blood Reviews, 2021, 46, 100738.	5.7	9
18	Prognostic significance of 8 weeks' relative dose intensity of lenvatinib in treatment of radioiodine-refractory differentiated thyroid cancer patients. Endocrine Journal, 2021, 68, 639-647.	1.6	9

#	Article	IF	CITATIONS
19	Clinical Impact of Cachexia in Head and Neck Cancer Patients Who Received Chemoradiotherapy. Cancer Management and Research, 2021, Volume 13, 8377-8385.	1.9	9
20	Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue Sarcoma. Cancers, 2021, 13, 6266.	3.7	9
21	Germline variants in pancreatic cancer patients with a personal or family history of cancer fulfilling the revised Bethesda guidelines. Journal of Gastroenterology, 2018, 53, 1159-1167.	5.1	7
22	Baseline Tumour Size as a Prognostic Factor for Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib. Anticancer Research, 2021, 41, 1683-1691.	1.1	7
23	Clinical features and treatment strategies for post-transplant and iatrogenic immunodeficiency-associated lymphoproliferative disorders. Blood Reviews, 2021, 49, 100807.	5.7	7
24	Pre-treatment Neutrophil-to-Lymphocyte Ratio Predicts Efficacy of Eribulin for Soft-tissue Sarcoma. Anticancer Research, 2021, 41, 527-532.	1.1	6
25	Establishment of preclinical chemotherapy models for gastroenteropancreatic neuroendocrine carcinoma. Oncotarget, 2018, 9, 21086-21099.	1.8	6
26	Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line. Molecular and Clinical Oncology, 2020, 14, 13.	1.0	6
27	Histological transformation in malignant lymphoma: a possible role of PET/CT and circulating tumor DNA as noninvasive diagnostic tools. Expert Review of Hematology, 2020, 13, 23-30.	2.2	4
28	Tumor growth rate as a prognostic factor for metastatic or recurrent adenoid cystic carcinoma of the head and neck patients treated with carboplatin plus paclitaxel. European Archives of Oto-Rhino-Laryngology, 2021, 278, 3037-3043.	1.6	4
29	Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients. Cancer Reports, 2021, 4, e1322.	1.4	4
30	Changes in Neutrophil-to-lymphocyte Ratio Predict Efficacy of Trabectedin for Soft-tissue Sarcoma. Cancer Diagnosis & Prognosis, 2021, 1, 303-308.	0.7	4
31	Japanese single-institution analysis of mitotane for patients with adrenocortical carcinoma. Endocrine Journal, 2021, 68, 1383-1390.	1.6	3
32	Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia. Bone Marrow Transplantation, 2022, 57, 874-880.	2.4	3
33	Platinum-doublet chemotherapy for advanced gastroenteropancreatic neuroendocrine carcinoma: a systematic review and meta-analysis. Discover Oncology, 2022, 13, .	2.1	3
34	Double-hit and double-expressor B-cell lymphomas: Current treatment strategies and impact of hematopoietic cell transplantation. Advances in Cell and Gene Therapy, 2018, 1, e13.	0.9	2
35	Clinical features and outcomes of metastatic pheochromocytoma treated by cytotoxic chemotherapy. Endocrine Journal, 2021, 68, 671-681.	1.6	2
36	An extragonadal germ cell tumor with dermatomyositis: A case report and literature review. Molecular and Clinical Oncology, 2020, 13, 1-1.	1.0	2

#	Article	IF	CITATIONS
37	A proposed clinical scoring system for initiation of lenvatinib treatment in radioiodine-refractory thyroid cancer patients. Endocrine, 2022, 76, 70-77.	2.3	2
38	Clinical feasibility of oral low-dose etoposide and sobuzoxane for conventional chemotherapy–intolerant lymphoma patients. Expert Review of Anticancer Therapy, 2021, 21, 715-722.	2.4	1
39	Genomic Profiles and Current Therapeutic Agents in Neuroendocrine Neoplasms. Current Drug Targets, 2020, 21, 389-405.	2.1	1
40	An extragonadal germ cell tumor with dermatomyositis: A case report and literature review. Molecular and Clinical Oncology, 2020, 13, 60.	1.0	1
41	Assessment of Pazopanib-Related Heart Failure in Patients With Advanced Soft Tissue Sarcoma ― A Single Institute Analysis ―. Circulation Journal, 2024, 88, 228-233.	1.6	1
42	Prognostic factors in patients with relapsed or refractory diffuse large B-cell lymphoma who underwent autologous stem-cell transplantation. Journal of Hematopoietic Cell Transplantation, 2016, 5, 93-101.	0.1	0
43	Current status of drug repositioning in hematology. Expert Review of Hematology, 2021, 14, 1005-1011.	2.2	O
44	Clinical features of young patients (below age 40) with pancreatic ductal adenocarcinoma Journal of Clinical Oncology, 2014, 32, 199-199.	1.6	0
45	Novel antibodies which have an impact on immune status after allogeneic hematopoietic cell transplantation. Expert Review of Hematology, 2022, , 1-7.	2.2	0
46	Platinum-doublet chemotherapy for advanced gastroenteropancreatic neuroendocrine carcinoma: A systematic review and meta-analysis Journal of Clinical Oncology, 2022, 40, e16217-e16217.	1.6	0